The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.
Posted inBusiness
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.